Page last updated: 2024-12-09

1-ethyl-3-methylimidazolium tetrafluoroborate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

## 1-Ethyl-3-methylimidazolium tetrafluoroborate: A Revolutionary Ionic Liquid

**1-ethyl-3-methylimidazolium tetrafluoroborate**, also known as **EMImBF4**, is an ionic liquid. This means it is a salt that exists in a liquid state at or near room temperature. It consists of a cation, 1-ethyl-3-methylimidazolium, and an anion, tetrafluoroborate.

**Why is it important for research?**

EMImBF4 and other ionic liquids have gained immense attention in research due to their unique properties:

* **Low vapor pressure:** Unlike conventional organic solvents, ionic liquids have negligible vapor pressure at room temperature, making them environmentally friendly and reducing the risk of volatile organic compound (VOC) emissions.
* **High ionic conductivity:** Ionic liquids possess high ionic conductivity, making them suitable for applications in electrochemical devices like batteries, fuel cells, and sensors.
* **Wide electrochemical window:** They have a wide electrochemical window, meaning they can withstand high voltages without decomposing, making them ideal for use in electrochemical processes.
* **Tunable properties:** By modifying the cation and anion, their properties can be tailored for specific applications.
* **Wide liquid range:** Many ionic liquids have large liquid ranges, allowing for reactions to be carried out at various temperatures.

**Research applications of EMImBF4:**

EMImBF4 is specifically used in various research areas, including:

* **Catalysis:** It serves as a solvent and catalyst in organic reactions, enhancing reaction rates and selectivity.
* **Electrochemistry:** It finds application in electrolyte solutions for batteries, fuel cells, and supercapacitors due to its high ionic conductivity.
* **Material science:** It's used in the synthesis of nanomaterials and the fabrication of functional coatings.
* **Biotechnology:** It's studied as a potential solvent for biocatalysis and for immobilization of enzymes.
* **Separation processes:** It's used in extraction and separation processes for purification and recovery of various compounds.

**Limitations:**

While ionic liquids have numerous advantages, they also have limitations:

* **Cost:** They are currently more expensive to produce than conventional solvents.
* **Viscosity:** Some ionic liquids have high viscosity, which can limit their use in certain applications.
* **Stability:** Some ionic liquids may be sensitive to moisture or air, limiting their long-term stability.

**Overall, EMImBF4 and other ionic liquids represent a promising new class of solvents with vast potential for numerous applications. Ongoing research aims to overcome their limitations and further explore their potential in various fields.**

1-ethyl-3-methylimidazolium tetrafluoroborate: an ionic liquid; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID2769348
CHEMBL ID3187488
SCHEMBL ID60788
SCHEMBL ID1238421
MeSH IDM0483028

Synonyms (38)

Synonym
c6h11bf4n2
1-ethyl-3-methylimidazolium tetrafluoroborate, for catalysis, >=98.5% (t)
1-ethyl-3-methylimidazolium tetrafluoroborate
AKOS005145780
E0496
143314-16-3
NCGC00260192-01
tox21_202644
dtxsid2049218 ,
dtxcid8029074
cas-143314-16-3
FT-0607752
emimbf4
CUNYTRQQXKCRTJ-UHFFFAOYSA-N
1-methyl-3-ethylimidazolium tetrafluoroborate
AKOS025310878
SCHEMBL60788
SCHEMBL1238421
1-ethyl-3-methyl-1h-imidazol-3-ium tetrafluoroborate
CHEMBL3187488
mfcd00216668
1-ethyl-3-methylimidazolium tetrafluoroborate, >=98% (hplc)
1-ethyl-3-methylimidazolium tetrafluoroborate, >=97.0% (hplc/t)
1-ethyl-3-methylimidazolium tetrafluoroborate, for electrochemistry, >=99.0% (hplc)
1-ethyl-3-methylimidazolium tetrafluoroborate (for molten salt)
ec 671-177-5
1-ethyl-3-methylimidazolium tetrafluoroborate, >=99%, <1000 ppm h2o
[emim]bf4
1-ethyl-3-methylimidazolium tetrafluoroborate salt
3-ethyl-1-methyl-1h-imidazol-3-ium tetrafluoroborate
1-ethyl-3-methylimidazol-3-ium;tetrafluoroborate
1-ethyl-3-methylimidazolium tetrafluoroborate [for molten salt]
AS-16075
AMY3528
H11269
A884988
1-ethyl 3-methylimidazolium tetrafluoroborate
1-propenyl-3-methylimidazolium tetrafluoroborate
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AR proteinHomo sapiens (human)Potency1.95680.000221.22318,912.5098AID743036
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency68.79890.003041.611522,387.1992AID1159552
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency68.79890.001530.607315,848.9004AID1224841
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (29)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's11 (37.93)29.6817
2010's16 (55.17)24.3611
2020's2 (6.90)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 33.38

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index33.38 (24.57)
Research Supply Index3.40 (2.92)
Research Growth Index4.61 (4.65)
Search Engine Demand Index40.78 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (33.38)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other29 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]